PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27764794-0	2016	The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.	quinone	89-96	delta/notch like EGF repeat containing	Homo sapiens	4-7	
27764794-2	2016	After screening a library of 2697 small molecule compounds, we found that two classes of compounds, the quinone-containing compounds such as nanaomycin and anti-microtubule drugs such as vincristine, exerted the best synergistic anticancer effects with the BET bromodomain inhibitor JQ1 in neuroblastoma cells.	quinone	104-111	delta/notch like EGF repeat containing	Homo sapiens	257-260	
27764794-3	2016	Mechanistically, the quinone-containing compound nanaomycin induced neuroblastoma cell death but also activated the Nrf2-antioxidant signaling pathway, and the BET bromodomain proteins BRD3 and BRD4 formed a protein complex with Nrf2.	quinone	21-28	delta/notch like EGF repeat containing	Homo sapiens	160-163	
34203690-2	2021	As a test, we coupled deep neural models for quinone formation, metabolite structures, and biomolecule reactivity to predict bioactivation pathways for 32 BET inhibitors and validate the bioactivation of select inhibitors experimentally.	quinone	45-52	delta/notch like EGF repeat containing	Homo sapiens	155-158	
34203690-10	2021	Nevertheless, our coupled modeling approach predicted BET inhibitor bioactivations including novel extended quinone methides, and we experimentally verified those pathways highlighting potential concerns for toxicity in the development of these new drug leads.	quinone	108-115	delta/notch like EGF repeat containing	Homo sapiens	54-57